The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

DKK 2016 | Current treatment of the leukemias

Name: Current treatment of the leukemias
Uploaded: 2016-02-25T00:00:00Z
Duration: 3 min 20 s
Description: At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, examines the recent progress in the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and myelodyplastic syndrome (MDS).

Rüdiger Hehlmann • 25 Feb 2016

DKK 2016

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Myelodysplastic Syndromes

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, examines the recent progress in the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and myelodyplastic syndrome (MDS).